Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma

JAMA Oncology

Volumn 3, Issue 6, 2017, Pages 774-783

  Connor, Ashton A ^a,c,d   Denroche, Robert E ^a,b   Jang, Gun Ho ^a,b,e   Timms, Lee ^a,b   Kalimuthu, Sangeetha N ^a   Selander, Iris ^c   McPherson, Treasa ^c   Wilson, Gavin W ^a   Chan Seng Yue, Michelle A ^a   Borozan, Ivan ^b   Ferretti, Vincent ^b   Grant, Robert C ^a,c   Lungu, Ilinca M ^b   Costello, Eithne ^f   Greenhalf, William ^f   Palmer, Daniel ^f   Ghaneh, Paula ^f   Neoptolemos, John P ^f   Buchler, Markus ^g   Petersen, Gloria ^h   Thayer, Sarah ⁱ   Hollingsworth, Michael A ^j   Sherker, Alana ^c,e   Durocher, Daniel ^c,e   Dhani, Neesha ^k   Hedley, David ^k   Serra, Stefano ^d   Pollett, Aaron ^c,l   Roehrl, Michael H A ^a,d,l   Bavi, Prashant ^a   Bartlett, John M S ^b   Cleary, Sean ^a,d   Wilson, Julie M ^a,b   Alexandrov, Ludmil B ^m,n   Moore, Malcolm ^l   Wouters, Bradly G ^d   McPherson, John D ^b,l   Notta, Faiyaz ^a   Stein, Lincoln D ^b,e   Gallinger, Steven ^a,c,d   more..

^a TORONTO GENERAL HOSPITAL   (Canada)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h MAYO CLINIC   (United States)

ⁱ MASSACHUSETTS GENERAL HOSPITAL   (United States)

^j UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^k PRINCESS MARGARET HOSPITAL   (Canada)

^l UNIVERSITY OF TORONTO   (Canada)

^m LOS ALAMOS NATIONAL LABORATORY   (United States)

ⁿ CENTER FOR NONLINEAR STUDIES   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; NUCLEAR PROTEIN; PALB2 PROTEIN, HUMAN; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR SUPPRESSOR PROTEIN;

AGED; CD8+ T LYMPHOCYTE; DOUBLE STRANDED DNA BREAK; DRUG EFFECTS; FEMALE; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MISMATCH REPAIR; MUTATION; PANCREAS CARCINOMA; PANCREAS TUMOR; PHYSIOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; TUMOR SUPPRESSOR GENE;

AGED; CARCINOMA, PANCREATIC DUCTAL; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; DNA BREAKS, DOUBLE-STRANDED; DNA MISMATCH REPAIR; FEMALE; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PROGNOSIS; PROGRAMMED CELL DEATH 1 RECEPTOR; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEINS;

EID: 85024399028     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.3916     Document Type: Article

References (63)

1. National Cancer Institute, Surveillance, Epidemiology, and End Results Program. SEER Stat Fact Sheets: Pancreas Cancer. http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed December 12, 2015.
2. Kalser MH, Ellenberg SS Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg. 1985; 120 (8):899-903.
3. Oettle H, Neuhaus P, Hochhaus A., et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013; 310(14):1473-1481.
4. Garrido-Laguna I., Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol. 2015; 12(6):319-334.
5. Von Hoff D.D., Ervin T, Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013; 369(18): 1691-1703.
6. Conroy T, Desseigne F, Ychou M., et al; Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-1825.
7. Brahmer JR, Tykodi SS, Chow L.Q., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. NEnglJMed. 2012; 366(26): 2455-2465.
8. Royal RE, Levy C, Turner K., et al. Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010; 33(8): 828-833.
9. Harder J, Ihorst G, Heinemann V., et al. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Br J Cancer. 2012; 106 (6):1033-1038.
10. Moore MJ, Goldstein D, Hamm J., et al; National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15):1960-1966.
11. da Cunha Santos G, Dhani N, Tu D, et al. Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer. 2010; 116(24):5599-5607.
12. Kim ST, Lim DH, Jang K.T., et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther. 2011; 10(10): 1993-1999.
13. Prat A, Pineda E, Adamo B., et al. Clinical implications of the intrinsic molecular subtypes of breast cancer. Breast. 2015; 24(suppl 2):S26-S35.
14. Devarakonda S, Morgensztern D, Govindan R. Genomic alterations in lung adenocarcinoma. Lancet Oncol. 2015; 16(7):e342-e351.
15. Biankin AV, Waddell N, Kassahn K.S., et al; Australian Pancreatic Cancer Genome Initiative. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012; 491 (7424):399-405.
16. Jones S, Zhang X, Parsons D.W., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008; 321(5897):1801-1806.
17. Witkiewicz AK, McMillan EA, Balaji U, et al Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets. Nat Commun. 2015; 6:6744.
18. Waddell N, Pajic M, Patch A.M., et al; Australian Pancreatic Cancer Genome Initiative. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature. 2015; 518(7540):495-501.
19. Collisson EA, Sadanandam A, Olson P., et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat Med. 2011; 17(4):500-503.
20. Moffitt RA, Marayati R, Flate E.L., et al. Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 2015; 47(10):1168-1178.
21. Bailey P, Chang DK, Nones K, et al; Australian Pancreatic Cancer Genome Initiative. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016; 531(7592):47-52.
22. Alexandrov LB, Nik-Zainal S, Wedge D.C., et al; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain. Signatures of mutational processes in human cancer. Nature. 2013; 500(7463):415-421.
23. Rooney MS, Shukla SA, Wu C.J., Getz G., Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61.
24. Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell. 2015; 161 (7):1681-1696.
25. Schulze K, Imbeaud S, Letouzé E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015; 47(5):505-511.
26. Van Allen E.M., Miao D, Schilling B., et al. Genomic correlates of response to CTLA-4 blockade in metastatic melanoma. Science. 2015; 350(6257):207-211.
27. Le DT, Uram JN, Wang H, et al PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015; 372(26):2509-2520.
28. Connor AA, Gallinger S. Hereditary pancreatic cancer syndromes. Surg Oncol Clin N Am. 2015; 24 (4):733-764.
29. International Cancer Genome Consortium. ICGC Data Portal. https://dcc.icgc.org/. Accessed November 1, 2015.
30. Alexandrov LB, Nik-Zainal S, Wedge D.C., Campbell PJ, Stratton MR. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 2013; 3(1):246-259.
31. Alexandrov LB, Jones PH, Wedge D.C., et al. Clock-like mutational processes in human somatic cells. Nat Genet. 2015; 47(12):1402-1407.
32. Ciccia A, Elledge SJ The DNA damage response: making it safe to play with knives. Mol Cell. 2010; 40(2):179-204.
33. Lord CJ, Ashworth A. BRCAness revisited. Nat Rev Cancer. 2016; 16(2):110-120.
34. Riazy M, Kalloger SE, Sheffield B.S., et al. Mismatch repair status may predict response to adjuvant chemotherapy in resectable pancreatic ductal adenocarcinoma. Mod Pathol. 2015; 28(10): 1383-1389.
35. Neoptolemos JP, Dunn JA, Stocken D.D., et al; European Study Group for Pancreatic Cancer. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet. 2001; 358(9293):1576-1585.
36. Neoptolemos JP, Stocken DD, Friess H, et al; European Study Group for Pancreatic Cancer. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N EnglJMed. 2004; 350(12):1200-1210.
37. Neoptolemos JP, Stocken DD, Bassi C, et al; European Study Group for Pancreatic Cancer. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA. 2010; 304(10):1073-1081.
38. Grant RC, Selander I, Connor A.A., et al. Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer. Gastroenterology. 2015; 148(3):556-564.
39. Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012; 487 (7407):330-337.
40. Kandoth C, Schultz N, Cherniack A.D., et al; Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature. 2013; 497(7447):67-73.
41. Muggia F, Safra T. 'BRCAness' and its implications for platinum action in gynecologic cancer. Anticancer Res. 2014; 34(2):551-556.
42. Bayraktar S, Glück S. Systemic therapy options in BRCA mutation-associated breast cancer. Breast Cancer Res Treat. 2012; 135(2):355-366.
43. Holter S, Borgida A, Dodd A., et al. Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma. J Clin Oncol. 2015; 33(28):3124-3129.
44. Campbell PJ, Yachida S, Mudie L.J., et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature. 2010; 467 (7319):1109-1113.
45. Bosetti C, Lucenteforte E, Silverman D.T., et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012; 23(7):1880-1888.
46. Nik-Zainal S., Davies H, Staaf J., et al. Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2016; 534 (7605):47-54.
47. G12D-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell. 2010; 18 (5):499-509.
48. Guinney J, Dienstmann R, Wang X., et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015; 21(11):1350-1356.
49. Banville N, Geraghty R, Fox E., et al. Medullary carcinoma of the pancreas in a man with hereditary nonpolyposis colorectal cancer due to a mutation of the MSH2 mismatch repair gene. Hum Pathol. 2006; 37(11):1498-1502.
50. Goggins M, Offerhaus GJ, Hilgers W, et al Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol. 1998; 152(6):1501-1507.
51. Wilentz RE, Goggins M, Redston M., et al. Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: a newly described and characterized entity. Am J Pathol. 2000; 156(5):1641-1651.
52. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature. 2011; 474(7353):609-615.
53. Ruscito I, Dimitrova D, Vasconcelos I., et al. BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients - a study of the Tumour Bank Ovarian Cancer (TOC) and Ovarian Cancer Diagnosis Consortium (OVCAD). Eur J Cancer. 2014; 50(12):2090-2098.
54. Kindler HL, Locker GY, Mann H, Golan T. POLO: a randomized phase III trial of olaparib tablets in patients with metastatic pancreatic cancer (mPC) and a germline BRCA1/2mutation (gBRCAm) who have not progressed following first-line chemotherapy. J Clin Oncol. 2015; 33(suppl):abstr TPS4149.
55. Hugo W, Zaretsky JM, Sun L, et al Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016; 165(1): 35-44.
56. Birkbak NJ, Kochupurakkal B, Izarzugaza J.M., et al. Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations. PLoS One. 2013; 8(11):e80023.
57. Jacobetz MA, Chan DS, Neesse A, et al Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut. 2013; 62(1):112-120.
58. Olive KP, Jacobetz MA, Davidson C.J., et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in amouse model of pancreatic cancer. Science. 2009; 324(5933):1457-1461.
59. Provenzano PP, Cuevas C, Chang A.E., Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012; 21(3):418-429.
60. Stromnes IM, Schmitt TM, Hulbert A, et al T cells engineered against a native antigen can surmount immunologic and physical barriers to treat pancreatic ductal adenocarcinoma. Cancer Cell. 2015; 28(5):638-652.
61. Jiang T, Sun Y, Yin Z., Feng S, Sun L, Li Z. Research progress of indolamine 2,3-dioxygenase inhibitors. Future Med Chem. 2015; 7(2):185-201.
62. Zhai L, Spranger S, Binder D.C., et al. Molecular pathways: targeting IDO1 and other tryptophan dioxygenases for cancer immunotherapy. Clin Cancer Res. 2015; 21(24):5427-5433.
63. Roberts NJ, Jiao Y, Yu J., et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov. 2012; 2(1):41-46.